225 related articles for article (PubMed ID: 35053417)
21. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
22. Cyclic peptide-selenium nanoparticles as drug transporters.
Nasrolahi Shirazi A; Tiwari RK; Oh D; Sullivan B; Kumar A; Beni YA; Parang K
Mol Pharm; 2014 Oct; 11(10):3631-41. PubMed ID: 25184366
[TBL] [Abstract][Full Text] [Related]
23. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
24. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study.
Ryu JS; Kratz F; Raucher D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762
[TBL] [Abstract][Full Text] [Related]
25. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
26. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
27. Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells.
Ai S; Jia T; Ai W; Duan J; Liu Y; Chen J; Liu X; Yang F; Tian Y; Huang Z
Br J Pharmacol; 2013 Apr; 168(7):1719-35. PubMed ID: 23146125
[TBL] [Abstract][Full Text] [Related]
28. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
29. Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine.
Nasrolahi Shirazi A; Tiwari RK; Oh D; Banerjee A; Yadav A; Parang K
Mol Pharm; 2013 May; 10(5):2008-20. PubMed ID: 23537165
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
[TBL] [Abstract][Full Text] [Related]
31. Comparative Molecular Transporter Efficiency of Cyclic Peptides Containing Tryptophan and Arginine Residues.
Hanna SE; Mozaffari S; Tiwari RK; Parang K
ACS Omega; 2018 Nov; 3(11):16281-16291. PubMed ID: 31458264
[TBL] [Abstract][Full Text] [Related]
32. Peptide amphiphile containing arginine and fatty acyl chains as molecular transporters.
Nasrolahi Shirazi A; Oh D; Tiwari RK; Sullivan B; Gupta A; Bothun GD; Parang K
Mol Pharm; 2013 Dec; 10(12):4717-27. PubMed ID: 24215132
[TBL] [Abstract][Full Text] [Related]
33. Intracellular trafficking and cytotoxicity of a gelatine-doxorubicin conjugate in two breast cancer cell lines.
Alvi MM; Nicoletto RE; Eshmawi BA; Kim HK; Cammarata CR; Ofner CM
J Drug Target; 2020 Jun; 28(5):487-499. PubMed ID: 31601131
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
35. Circumventing Doxorubicin Resistance Using Elastin-like Polypeptide Biopolymer-Mediated Drug Delivery.
Dragojevic S; Turner L; Raucher D
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216417
[TBL] [Abstract][Full Text] [Related]
36. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model.
Gou Y; Zhang Z; Li D; Zhao L; Cai M; Sun Z; Li Y; Zhang Y; Khan H; Sun H; Wang T; Liang H; Yang F
Drug Deliv; 2018 Nov; 25(1):321-329. PubMed ID: 29350051
[TBL] [Abstract][Full Text] [Related]
37. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
Joshi M; Choi JS; Park JW; Doh KO
J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295
[TBL] [Abstract][Full Text] [Related]
38. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms.
Lei T; Srinivasan S; Tang Y; Manchanda R; Nagesetti A; Fernandez-Fernandez A; McGoron AJ
Nanomedicine; 2011 Jun; 7(3):324-32. PubMed ID: 21094277
[TBL] [Abstract][Full Text] [Related]
39. Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil
Cagel M; Bernabeu E; Gonzalez L; Lagomarsino E; Zubillaga M; Moretton MA; Chiappetta DA
Biomed Pharmacother; 2017 Nov; 95():894-903. PubMed ID: 28903185
[TBL] [Abstract][Full Text] [Related]
40. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage.
Shi NQ; Gao W; Xiang B; Qi XR
Int J Nanomedicine; 2012; 7():1613-21. PubMed ID: 22619516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
